Ironwood Pharmaceuticals (NASDAQ:IRWD) had its target price cut by Jefferies Group from $12.00 to $11.00 in a report issued on Thursday, Analyst Ratings.Net reports. They currently have a hold rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated an outperform rating on shares of Ironwood Pharmaceuticals in a research note to investors on Thursday. They now have a $12.00 price target on the stock. Separately, analysts at Cowen and Company upgraded shares of Ironwood Pharmaceuticals from a market perform rating to an outperform rating in a research note to investors on Thursday. They now have a $14.00 price target on the stock. Finally, analysts at Wedbush cut their price target on shares of Ironwood Pharmaceuticals from $12.00 to $10.00 in a research note to investors on Wednesday, October 23rd. They now have a neutral rating on the stock. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. Ironwood Pharmaceuticals currently has an average rating of Hold and a consensus target price of $13.59.
Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 10.03 on Thursday. Ironwood Pharmaceuticals has a 52-week low of $9.83 and a 52-week high of $19.67. The stock has a 50-day moving average of $11.89 and a 200-day moving average of $13.81. The company’s market cap is $1.211 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Tuesday, October 22nd. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. The company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $6.54 million. During the same quarter in the previous year, the company posted $0.42 earnings per share. The company’s revenue for the quarter was down 94.9% on a year-over-year basis. On average, analysts predict that Ironwood Pharmaceuticals will post $-2.44 earnings per share for the current fiscal year.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.